News & Events

DoD KCRP Funding: Webinar for Kidney Cancer Researchers

**Date:** June 26, 2018  
**Time:** 2:00–3:00 p.m. Eastern Time  
**Host:** American Urological Association  
**Presenter:** Dr. Donna M. Kimbark, CDMRP Program Manager  
**Target Audience:** Kidney cancer researchers from all disciplines  

Join the American Urological Association (AUA) and CDMRP Program Manager Dr. Donna Kimbark for an informational webinar on applying for research funding through the Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP) Kidney Cancer Research Program. This webinar is a valuable tool for anyone seeking support for kidney cancer research.

Register Now

---

Health Research Grant Competitions

*Programs administered by Health Research Services, unless otherwise indicated. Email: [hsresadm@mcmaster.ca](mailto:hsresadm@mcmaster.ca)*

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>NEW</em> CIHR – Operating Grant: Rapid Research Response Fund for Ebola</td>
<td>Jun 29</td>
<td>Jul 13</td>
<td></td>
</tr>
<tr>
<td><em>UPDATED</em> CIHR – Operating Grant: AMR: Point of Care Diagnostics in Human Health – Phase 2</td>
<td>Aug 7</td>
<td>Aug 21</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: Understanding the Health Impact of Inactivity</td>
<td>Jul 24</td>
<td>Aug 7</td>
<td>Aug 21</td>
</tr>
<tr>
<td>CIHR – Team Grant: Pathways Implementation Research Teams Component 3</td>
<td>Aug 23</td>
<td>Sep 6</td>
<td></td>
</tr>
<tr>
<td>CIHR – Fellowship: Banting Postdoctoral Fellowships Program</td>
<td></td>
<td></td>
<td>Contact Graduate Studies</td>
</tr>
<tr>
<td>CIHR - Operating Grant: Epigenetics Clinical Translation</td>
<td>Sep 5</td>
<td>Sep 26</td>
<td>Oct 10</td>
</tr>
<tr>
<td>CIHR – Team Grant: HIV/AIDS Biomedical and Clinical Research</td>
<td>Oct 23</td>
<td>Nov 6</td>
<td></td>
</tr>
<tr>
<td>CIHR – Centres for HIV/AIDS, Hepatitis C and other STBBIs Research</td>
<td>Nov 27</td>
<td>Dec 11</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (Non-CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Royal-Mach-Gaensslen Prize for Mental Health Research</td>
<td>Jul 1</td>
<td>Jul 15</td>
<td></td>
</tr>
<tr>
<td>Canadian Blood Services: Blood Efficiency Accelerator Award Program</td>
<td>Jul 1</td>
<td>Jul 15</td>
<td></td>
</tr>
<tr>
<td>Escher Fund for Autism: Grants</td>
<td>Jun 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elton John Aids Foundation: Open Call for Proposals</td>
<td>Jun 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding Organization</td>
<td>Program Title</td>
<td>Start Date</td>
<td>End Date</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------------------------------------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>National Multiple Sclerosis Society</td>
<td>Research Grants</td>
<td>Jul 25</td>
<td>Jul 25</td>
</tr>
<tr>
<td></td>
<td>Harry Weaver Neuroscience Scholar Awards</td>
<td>Aug 8</td>
<td>Aug 8</td>
</tr>
<tr>
<td></td>
<td>Collaborative MS Research Centers</td>
<td>Aug 30</td>
<td>Aug 30</td>
</tr>
<tr>
<td>Crohn’s &amp; Colitis Foundation</td>
<td>Biology of Fibrosis in IBD RFP</td>
<td>Aug 24</td>
<td>Aug 24</td>
</tr>
<tr>
<td>Crohn’s &amp; Colitis Foundation</td>
<td>Novel Technologies Initiative</td>
<td>Aug 24</td>
<td>Aug 24</td>
</tr>
<tr>
<td>National Multiple Sclerosis Society</td>
<td>Pilot Research Grants</td>
<td>Sep 10</td>
<td>Sep 10</td>
</tr>
<tr>
<td>Autism Speaks 2018 Treatment Research Grants</td>
<td></td>
<td>Jul 18</td>
<td>Sep 5</td>
</tr>
<tr>
<td>QUEST Resident Resource Opportunity</td>
<td></td>
<td>Sep 7</td>
<td>Sep 7</td>
</tr>
<tr>
<td>Alex’s Lemonade Stand Foundation</td>
<td>Familial RUNX1 Research Program</td>
<td>Jul 2</td>
<td>Sep 17</td>
</tr>
<tr>
<td>BrightFocus Foundation</td>
<td>Macular Degeneration Research Grants</td>
<td>Jun 26</td>
<td>Oct 2</td>
</tr>
<tr>
<td>Natural Sciences and Engineering Research Council of Canada (NSERC)</td>
<td>Discovery Grants Program</td>
<td>Jul 18 NOI to ROADS</td>
<td>Aug 1 NOI to NSERC</td>
</tr>
<tr>
<td>Weston Brain Institute</td>
<td>Rapid Response: Canada 2019 (Parkinson’s &amp; Related Diseases)</td>
<td>Aug 1</td>
<td>Oct 29</td>
</tr>
<tr>
<td>Weston Brain Institute</td>
<td>Transformational Research: Canada 2019 (Parkinson’s &amp; Related Diseases)</td>
<td>Aug 1</td>
<td>Oct 29</td>
</tr>
<tr>
<td>Burroughs Wellcome Fund</td>
<td>Investigators in the Pathogenesis of Infectious Disease (PATH) Award</td>
<td>Jul 16</td>
<td>Nov 1</td>
</tr>
<tr>
<td>Canadian Glycomics Network (GlycoNet)</td>
<td>GlycoNet Request for Proposals – Cycle II</td>
<td>Jul 3</td>
<td>Jan 18 2019</td>
</tr>
<tr>
<td>Leukemia &amp; Lymphoma Society</td>
<td>Specialized Centre of Research Program</td>
<td>Aug 31</td>
<td>Feb 1 2019</td>
</tr>
<tr>
<td>Lyle Spencer Research Awards</td>
<td></td>
<td>Oct 2</td>
<td>TBD</td>
</tr>
<tr>
<td>Weston Brain Institute</td>
<td>Postdoctoral Scholars at Oxford</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute</td>
<td>International Fellowships: Canada</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>Weston Brain Institute</td>
<td>Big Ideas: Canada</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA)</td>
<td>Matching Funds for Research Opportunities</td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>MITACS Accelerate Fellowship</td>
<td></td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>Weston Brain Institute: Early Phase Clinical Trials: Canada</td>
<td></td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>OCE Voucher for Innovation and Productivity (VIP I) Program</td>
<td></td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>OCE Voucher for Innovation and Productivity II (VIP II) Program</td>
<td></td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>MITACS Accelerate Program</td>
<td></td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>MITACS Globalink Partnership Award</td>
<td></td>
<td>Ongoing</td>
<td>MILO</td>
</tr>
<tr>
<td>Funding Opportunity (DoD)</td>
<td>LOI Deadline</td>
<td>Internal HRS Deadline</td>
<td>Sponsor Deadline</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 11</td>
<td>Jul 19</td>
<td>Aug 2</td>
</tr>
<tr>
<td>Department of Defense Neurofibromatosis Research Program (NFRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 26</td>
<td>Aug 2</td>
<td>Aug 9</td>
</tr>
<tr>
<td>Department of Defense Ovarian Cancer Research Program (OCRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 25</td>
<td>Aug 1</td>
<td>Aug 8</td>
</tr>
<tr>
<td>Department of Defense Medical Simulation and Information Sciences Research Program (JPC-1) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 25</td>
<td>Aug 31</td>
<td>Sep 17</td>
</tr>
<tr>
<td>Department of Defense Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 25</td>
<td>Sep 13</td>
<td>Sep 27</td>
</tr>
<tr>
<td>Department of Defense Peer Reviewed Cancer Research Program (PSCRPRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Aug 28</td>
<td>Sep 12</td>
<td>Sep 26</td>
</tr>
<tr>
<td>Department of Defense Tick-Borne Disease Research Program (TBDRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 25</td>
<td>Sep 13</td>
<td>Sep 27</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) Funding Opportunities for Fiscal Year 2018</td>
<td>Sep 20</td>
<td>Sep 27</td>
<td>Oct 4</td>
</tr>
<tr>
<td>Department of Defense Autism Research Program (ARP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 5</td>
<td>Sep 20</td>
<td>Oct 4</td>
</tr>
<tr>
<td>Department of Defense Epilepsy Research Program (ERP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 26/Sept 20</td>
<td>Sep 20/27</td>
<td>Oct 4</td>
</tr>
<tr>
<td>Department of Defense Spinal Cord Injury Research Program (SCIRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 9</td>
<td>Oct 1</td>
<td>Oct 15</td>
</tr>
<tr>
<td>Department of Defense Multiple Sclerosis Research Program (MSRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 16</td>
<td>Oct 18</td>
<td>Nov 1</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) Funding Opportunities for Fiscal Year 2018</td>
<td>Aug 6</td>
<td>Oct 11</td>
<td>Oct 25</td>
</tr>
<tr>
<td><em>NEW</em> Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) Funding Opportunities for Fiscal Year 2018</td>
<td>Aug 16</td>
<td>Oct 18</td>
<td>Nov 1</td>
</tr>
<tr>
<td>Department of Defense Bone Marrow Failure Research Program (BMFRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 10</td>
<td>Oct 24</td>
<td>Nov 7</td>
</tr>
<tr>
<td>Department of Defense Lupus Research Program (LRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Aug 29/Nov 14</td>
<td>Nov 21</td>
<td>Dec 5</td>
</tr>
</tbody>
</table>
CIHR – Operating Grant: Rapid Research Response Fund for Ebola

The Rapid Research Response Fund for Ebola is expected to:

- Enhance the mobilization of interdisciplinary Canadian and African health and social scientists and humanists, as well as knowledge users, to help contain the current Ebola Virus Disease outbreak in the DRC;
- Enhance the adaptive scaling of successful interventions in curbing Ebola transmission (and other diseases of similar relevance), and support the exploration of novel approaches to remaining challenges of outbreak mitigation and control;
- Improve understanding of an effective role for international agencies in preventing and responding to Ebola Virus Disease outbreaks in Africa, including how international institutions can better engage local leadership to ensure that responses are culturally appropriate, community specific, and leverage local characteristics; and,
- Support collaboration and policy making that promote evidence-based practices to prevent or mitigate the impact of future Ebola threats in the DRC and surrounding region.

Funding Details: IDRC, CIHR and SSHRC will contribute to a total CAN$1.5 million towards this Rapid Research Response Fund. A minimum of four successful teams will be eligible to receive Research Grants up to CAN$360,000 over two years (2018-2020).

Additional Details
Internal HRS Deadline: June 29, 2018
Sponsor Deadline: July 13, 2018

CIHR – Operating Grant: AMR: Point of Care Diagnostics in Human Health – Phase 2

The Antimicrobial Resistance: Point of Care Diagnostics in Human Health Phase 2 funding opportunity is expected to:

- Improve rational use of antibiotics and clinical management by increasing availability, timeliness, and uptake of clinically relevant point-of-care diagnostic tools in AMR.
- Integrate evidence-informed therapeutic approaches and prevention interventions into health care practice and policy.
- Determine commercial viability and show direct clinical applicability of a technology or tool that has passed the preliminary design developmental phase.
- Enhance capacity to conduct international, intersectoral and interdisciplinary AMR research through collaboration and training of researchers and health care professionals.

Funding Details: The total amount available for this funding opportunity is $2,025,000, enough to fund approximately 3 grants. The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.

Additional Details
Internal HRS Deadline: August 7, 2018
Sponsor Deadline: August 21, 2018

CIHR – Operating Grant: Understanding the Health Impact of Inactivity

The ultimate goals of this call are to develop solutions for:

- Older adults experiencing periods of inactivity in order to inform transitions in care and/or improve their quality of life.
- Astronauts in order to stay in good health during spaceflights and during their extended stays in the International Space Station, as well as in the foreseen deep space exploration program.

The objectives of the Understanding the Health Impacts of Inactivity funding opportunity are to:

1. Enhance our understanding of the
   - Health impacts of inactivity by:
     - Identifying impact through biological measures
     - Identifying relevant biological measures to support care transitions
     - Identifying biological changes that may inform our mechanistic understanding of pre-frailty and progression to frailty

   And
   - Impact and effectiveness of a specific countermeasure protocol by:
     - Identifying biological changes induced by its use
     - Evaluating the effectiveness of the countermeasure
     - Generating new knowledge to further inform the development of interventions and rehabilitation solutions to counteract the adverse effects of inactivity
For older people and individuals who experience inactivity or reduced activity over an extended period, and for astronauts during space missions.

2. Build capacity of the next generation of researchers through the meaningful involvement of trainees and/or early career investigators in the research program.

**Funding Details:** The total amount available for this funding opportunity is $1,600,000, enough to fund approximately 8 grants. The maximum amount per grant is $200,000 for up to 18 months.

**Additional Details**

**LOI Deadline:** July 24, 2018  
**Internal HRS Deadline:** August 7, 2018  
**Sponsor Deadline:** August 21, 2018

**CIHR – Team Grant: Pathways Implementation Research Teams Component 3**

The specific objectives of the Team Grant: Pathways Implementation Research Team Component 3 funding opportunity are to:

- Increase the equitable reach, access and sustainability of culturally appropriate population health interventions using an implementation science approach
- Develop and share recommendations, guidelines and policies for sustainability and enhanced equitable reach and access of interventions that incorporate reciprocal learning between participating Indigenous communities and research teams
- Build capacity for implementation research in Indigenous communities by training and mentoring junior researchers through partnerships with communities, including students and trainees with Indigenous living experience, and community members

**Funding Details:** The total amount available for this funding opportunity is $3,000,000, enough to fund approximately 2 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $300,000 per year for up to 5 years, for a total of $1,500,000 per grant. Applicants must secure partner contribution from non-federal sources to match the CIHR contribution at a minimum of 25% of the total grant amount requested as cash and/or in-kind.

**Additional Details**

**Internal HRS Deadline:** August 23, 2018  
**Sponsor Deadline:** September 6, 2018

**CIHR – Clinical Trials Network in HIV/AIDS (2018)**

The Clinical Trials Network in HIV/AIDS is expected to:

- Develop and implement a strategic, outcome-oriented clinical trials research agenda to ensure alignment with current and emerging priorities in HIV, hepatitis C and/or other STBBIs and related health conditions;
- Sustain a high quality national infrastructure (including methodological expertise, data management and analysis, research support staff and regulatory expertise) to enable Canadian researchers to collaboratively and efficiently conduct innovative and excellent clinical trials and related research across Canada and internationally;
- Accelerate the translation and uptake of new knowledge into clinical applications and guidelines for patient care to support the adoption of best practices by clinicians, caregivers and patients;
- Engage stakeholders and partners (including people living with HIV, hepatitis C and/or other STBBIs; community organizations; Indigenous peoples; clinicians; policy makers; and relevant national networks) in CTN activities and governance committees to ensure their active and meaningful involvement;
- Strengthen Canadian research capacity to conduct and apply clinical research through training and mentoring initiatives; and
- Strengthen the networking and partnership strategies and secure additional funding to maximize the impact and outcomes of the Network and work toward sustainability.

**Eligibility:**

- Since this funding opportunity is a directed grant, only the CIHR Canadian HIV Trials Network (CTN) is eligible to apply.  
- The Nominated Principal Applicant must be an independent researcher. The Nominated Principal Applicant will serve as the National Director of the CTN.  
- The Nominated Principal Applicant must be appointed at an eligible institution (See Institutional Eligibility Requirements for eligibility process and associated timelines) at the time of application.
• At least two other Principal Applicants, to be National Co-Directors, must be independent researchers. The members of the leadership team (i.e., National Director and Co-Directors) must be located in at least three different CIHR-eligible institutions, in two or more provinces/territories.
• At the time of application, one new Core co-lead for each Core must be clearly identified in the Participant table.

**Funding Details:** The total amount available for this funding opportunity is $22,850,000, enough to fund 1 grant. This amount may increase if additional funding partners participate. The maximum amount is $4,570,000 per year for up to 5 years.

**Additional Details**
Internal HRS Deadline: **August 28, 2018**
Sponsor Deadline: **September 11, 2018**

**CIHR – Fellowship: Banting Postdoctoral Fellowships Program**
The fellowships will be known as the Banting Postdoctoral Fellowships, in memory of Sir Frederick Banting, the Canadian physician, researcher, Nobel laureate and war hero who, together with his assistant Dr. Charles Best, is credited with the discovery of insulin. The Banting Postdoctoral Fellowships program provides funding to the very best postdoctoral applicants, both nationally and internationally, who will positively contribute to the country's economic, social and research-based growth. The program is jointly administered by Canada’s three federal granting agencies: the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC). CIHR has been designated as the operational lead for the implementation of the program.

**Funding Details:** The total amount available for this funding opportunity is $9,800,000, enough to fund approximately 70 awards. The maximum amount per award is $70,000 (taxable) per year, for up to two (2) years and a total of $140,000 per award. The funding is not renewable.

**Additional Details**
Contact [Correen Smith](#) in Graduate Studies to Apply
Sponsor Deadline: **September 19, 2018**

**CIHR - Operating Grant: Epigenetics Clinical Translation**
The specific objectives of this funding opportunity are to:
• Evaluate applications of epigenetics in the clinical setting, including through clinical trials, demonstrating proof-of-concept utility of epigenetic changes as biomarkers, diagnostics and targets for potential therapeutics;
• Support and build upon existing Canadian research expertise in epigenetics for clinical translation outcomes;
• Build capacity for epigenetics clinical research through training and mentoring.

**Funding Details:** The total amount available for this funding opportunity is $6,000,000, enough to fund up to four grants. The maximum amount per grant is $375,000 per year for up to four years.

**Additional Details**
LOI Deadline: **September 5, 2018**
Internal HRS Deadline: **September 26, 2018**
Sponsor Deadline: **October 10, 2018**

**CIHR – Team Grant: HIV/AIDS Biomedical and Clinical Research**
The Team Grant: HIV/AIDS Biomedical Clinical Research funding opportunity is expected to contribute to the global search for a safe and effective cure for HIV, and to develop prevention strategies and tools. The specific objectives of this funding opportunity are to:
• transform HIV biomedical and clinical research in Canada into a collaborative, interdisciplinary model of knowledge creation and application through the funding of innovative research programs;
• create an inclusive and sustainable pipeline of HIV research capacity from across disciplines, sectors, and perspectives (e.g., HIV basic scientists, clinical investigators, knowledge users and/or community members [people living with HIV]);
• effectively translate knowledge into clinical and/or commercial applications which contribute to the design, development and evaluation of research strategies; and
• create a critical mass of technical and scientific expertise in Canada that engages meaningfully with one another and with relevant national stakeholders, and participates in international research efforts.
**Funding Details:** The total amount available for this funding opportunity is $20,000,000, enough to fund approximately 6 grants.

**Additional Details**

**Internal HRS Deadline:** October 23, 2018  
**Sponsor Deadline:** November 6, 2018

---

**CIHR – Centres for HIV/AIDS, Hepatitis C and other STBBIs Research**

The Centres for HIV/AIDS, Hepatitis C and other STBBIs Research are expected to improve health and access to effective programs and services for people living with and at risk of HIV, Hepatitis C and other STBBIs, particularly for populations most affected. The specific objectives of the Centres are to:

- foster coordination of research efforts by developing and supporting a network of collaborative Centres;
- develop and/or strengthen high quality infrastructure for implementation science, health services and population health research to enable Canadian HIV, Hepatitis C and other STBBI researchers to conduct innovative, high quality, collaborative research;
- facilitate implementation science, health services and population health research training and mentoring initiatives to strengthen the capacity of trainees; and
- accelerate the translation and uptake of knowledge and implementation of evidence to inform practices, policies and programs through models of integrated knowledge translation and innovative strategies that engage stakeholders and partners (including people living with HIV, community organizations, clinicians, policy makers and relevant networks).

**Funding Details:** The total amount available for this funding opportunity is $10,000,000, enough to fund approximately two to three grants. This amount may increase if additional funding partners participate. Centres may be variable in size; it is anticipated that requested budgets will range from $400,000 to $1,000,000 per annum. The maximum amount per grant is $1,000,000 per year for up to 5 years for a total of $5,000,000 per grant.

**Additional Details**

**Internal HRS Deadline:** November 27, 2018  
**Sponsor Deadline:** December 11, 2018

---

**The Royal-Mach-Gaensslen Prize for Mental Health Research**

The Royal-Mach-Gaensslen Prize for Mental Health Research was established in 2015 and is awarded annually to recognize and support rising star Canadian research scientists with a focus in the area of mental health. This annual national Prize provides funding to outstanding rising star researchers who are affiliated with a Canadian academic or clinical research institution in the field of mental health, to encourage them to continue to pursue their research interests in Canada. It recognizes those with a demonstrated track record in research with excellence in scientific rigor, innovative thinking, imagination and originality and a clear ability to work in partnership with other disciplines and/or research teams external to the institution with which they are affiliated. This competition will occur once a year for 10 years.

**Funding Details:** $100,000 for one year

**Additional Details**

**Internal HRS Deadline:** July 1, 2018  
**Sponsor Deadline:** July 15, 2018

---

**Canadian Blood Services: Blood Efficiency Accelerator Award Program**

The objective of the Canadian Blood Services’ Blood Efficiency Accelerator Award Program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system. To achieve this objective, the Program will support innovative research projects that seek new knowledge or accelerate the application of existing knowledge. In the context of this competition, blood product is defined as a therapeutic product derived from the donation of blood or blood components and includes red blood cell and platelet concentrates, plasma and plasma derivatives (including plasma protein products), and hematopoietic stem cells (including those derived from cord blood).

**Funding Details:** Canadian Blood Services has allocated $60,000 per year for the Blood Efficiency Accelerator Award Program and anticipate funding two (2) projects annually at a maximum value of $30,000 per project.
Escher Fund for Autism: Grants
The Escher Fund for Autism has recently announced two Requests for Proposals (RFP):
1) Examining molecular impacts of drug exposures on developing germline, and implications for nongenetic inheritance - the objective: to support projects that directly focus on early (primordial germ cell in embryo through neonatal period) germline molecular impacts of high and sustained dose pregnancy drugs.
2) Intensive investigation of multi-hit families affected by autism and related neurodevelopmental disorders - the objective: to support intensive investigation into exposure histories and characteristics of “multi-hit families” with three or more children (including half-siblings) affected by autism and related disorders. The related disorders include but are not limited to attention deficit hyperactivity disorder, Asperger’s, learning disabilities and intellectual disability, social-communication impairments, speech and language impairments, oppositional defiant disorder, intermittent explosive disorder, mood disorders, anxiety, depression, schizophrenia spectrum and psychotic disorders.

Funding Details: $25,000 grant available.

Elton John Aids Foundation: Open Call for Proposals
The objective of the Open Call for Proposals is to support
1) any organization working to address HIV and AIDS, and
2) organizations working toward one or more of the following goals:
   - Wellness: Improving the health of people living with HIV or at risk, or otherwise affected by HIV
   - Rights: Upholding the rights of people living with and affected by HIV
   - Quality of Life: addressing the social and economic needs of people living with and affected by HIV
   - Resilience: strengthening the skills and strategies of organizations and activists addressing HIV

The EJAF values programs that:
   - are led by and based in the communities being served;
   - are advocating for improved government health policies and funding;
   - are piloting or scaling up innovative programs to promote health and rights;
   - can show a history of activism, creativity and urgency in working to address and curtail the HIV epidemic;
   - are grounded in evidence regarding where and among whom HIV infections are happening, and the best interventions to help people avoid infection or, if HIV-positive, to live healthy lives.

Funding Details: First-time applicants should apply for grants of between $20,000 and $100,000 for 1 year. The EJAF will consider requests up to $300,000 from organizations with a national focus or working in multiple countries, and have a proven ability to implement large-scale programs.

National Multiple Sclerosis Society: Research Grants
Research Grants, the objective: to support applications for studies that may serve to advance their mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation.

Funding Details: applicants are required to submit an estimate of the total cost of the proposed project, during the given cycle.
National Multiple Sclerosis Society: Harry Weaver Neuroscience Scholar Awards
Harry Weaver, Ph.D., known worldwide for his contribution to neurosciences and multiple sclerosis research, was the Society's Director of Research from 1966-1977. Throughout his tenure with the Society and throughout his career, Dr. Weaver continued to encourage young investigators to enter and pursue MS research, and to broaden our understanding of basic and clinical aspects of MS. In recognition of Dr. Weaver's contribution to the neurosciences and MS research, and to his dedication to young researchers, the Society named this prestigious Award in his honor.

Funding Details: Maximum $30,000 in year 1 and may increase by $2,500 in subsequent years to a maximum of $40,000 in year 5.

Additional Details
LOI Deadline: August 8, 2018
Internal HRS Deadline: August 8, 2018
Sponsor Deadline: August 15, 2018

National Multiple Sclerosis Society: Collaborative MS Research Centers
Collaborative MS Research Centers, the objective: to help stimulate collaboration and interaction in MS research among independent investigators, strengthen the ties between basic and clinical research, and stimulate recruitment of researchers from other fields in MS research.

Funding Details: Applicants are required to submit an estimate of the total cost of the proposed project for the first year and to the extent possible for subsequent years, with a maximum of $150,000 per year for a 5 year term.

Additional Details
LOI Deadline: August 30, 2018
Internal HRS Deadline: August 30, 2018
Sponsor Deadline: September 5, 2018

Crohn’s & Colitis Foundation Biology of Fibrosis in IBD RFP
The Crohn’s & Colitis Foundation seeks to fund studies focused on investigating the biological mechanisms leading to, and protecting from, fibrosis in IBD. These studies should be built upon clinical observations and/or published evidence in human IBD. Particular interest will be on proposals that address one or more of the following areas:

- Pathophysiology of fibrosis based on documented patterns of gene expression
- Cell biological mechanisms of fibrosis – role of different cell types
- Biology of strictureplasty

Funding Details: $900,000 for three years ($300,000/year, contingent on reaching annual milestones)

Additional Details
Internal HRS Deadline: August 24, 2018
Sponsor Deadline: September 7, 2018

Crohn’s & Colitis Foundation Novel Technologies Initiative
The purpose of this initiative is to support the development of sensor technologies that can be implemented to detect and monitor inflammation in the context of IBD. Proposed technology should meet the following criteria:

- Minimally invasive detection of active inflammation. Preferably, the signals detected should be related to biological processes regarded to be causative and/or highly correlated with intestinal inflammation in IBD (e.g. cytokine levels, presence of proinflammatory immune cells, proinflammatory mediators, etc.) and should be informative with respect to symptoms (e.g. active "flare-up" prior to observation of severe symptoms).
- Sampling of data should be continuous or periodic during daily life, specifically, technologies, such as sensors/ biosensors/ nano-sensors, implantable, ingestible, wearable or environmental devices, will be considered.
- Have the potential to reach clinical studies within the next 3-4 years.
**Funding Details:** $125,000 for one year (inclusive of 10% indirect cost)

**Additional Details**

Internal HRS Deadline: August 24, 2018  
Sponsor Deadline: September 7, 2018

**National Multiple Sclerosis Society: Pilot Research Grants**

Pilot Research Grants, the objective: to fund high-risk pilot grants to quickly test novel ideas. Funding is provided for one year to test innovative, cutting-edge ideas or untested methods, and to gather sufficient preliminary data to apply for longer-term funding.

**Funding Details:** Maximum $50,000 for 1 year

**Additional Details**

LOI Deadline: September 10, 2018  
Internal HRS Deadline: September 10, 2018  
Sponsor Deadline: September 12, 2018

**Autism Speaks 2018 Treatment Research Grants**

Autism Speaks invites Treatment Research Grant applications to conduct innovative studies of novel treatments and interventions for people with autism spectrum disorder (ASD) throughout the life span. These may include medical approaches such as pharmacological treatments and complementary and alternative forms of health care, as well as behavioral and/or psychosocial interventions. Successful applications will focus on evaluation of the efficacy, effectiveness or other therapeutic benefits of the targeted intervention.

**Funding Details:** Two awards are anticipated at $250,000/year for three years with a maximum of $750,000 per award.

**Additional Details**

LOI Deadline: July 18, 2018  
Internal HRS Deadline: September 5, 2018  
Sponsor Deadline: September 19, 2018

**QUEST Resident Research Resource Opportunity**

Hamilton Health Sciences and McMaster University’s commitment to quality research and patient care led to the creation of the QUEST Resident Research Resource. This fund provides a unique opportunity to support resident investigators under the mentorship of senior staff, coupled with support in KT/Health Services research.

The primary objective of QUEST is to support the development and evaluation of simple, cost-effective resident initiated cardiovascular KT interventions. The Quest Framework would utilize KT research and the knowledge to action cycle (Graham et al) to address key evidence-practice gaps in the following realms:

1. **Quality:** Applying best care and developing effective tools for continuous quality improvement.
2. **Utilization:** Optimizing the use of needed investigations/treatments. Reducing unnecessary or even harmful investigations/treatments. Maximizing productivity, human and physical resources.
3. **Evidence:** Developing simple, cost-effective toolkits to optimize the delivery of evidence-based medicine.
4. **Safety:** Continuous risk assessment and risk management.
5. **Translational:** The use of KT research skills to disseminate lessons learned.

**Funding Details:** Up to 2 projects may receive a maximum of $10,000 depending on the number and quality of submissions.

Internal HRS Deadline: September 7, 2018  
Sponsor Deadline: September 21, 2018  
*For additional information and to apply, contact Susie Hanson at shanson@mcmaster.ca*

**Alex’s Lemonade Stand Foundation Familial RUNX1 Research Program**

ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation ([runx1.com](http://runx1.com)) is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML.
Patient-Centered Outcomes Research Institute (PCORI) Implementation of Effective Shared Decision Making Approaches in Practice Settings – Cycle 2 2018

This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance of shared decision making. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely-accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. Patients and others whose involvement is central to success of the proposed project should be involved in its design and execution. In addition, applicants should assure that the proposed project team draws on sufficient expertise in both shared decision making and implementation science. Projects must incorporate rigorous evaluation of the implementation of shared decision making approaches, as well as the impact of the shared decision making processes in the targeted settings.

Funding Details: Total Direct costs, $1.5 Million. Funds available up to $6.5 Million. Maximum Project Period is up to 3 years.

BrightFocus Foundation: Macular Degeneration Research Grants

The objective of the Macular Degeneration Research Program is to support
1) pioneering research leading to a greater understanding, prevention and treatment of age-related macular degeneration,
2) exciting pilot projects that have already generated some amount of preliminary data, however, would not at their present stage be competitive for large government or industry awards, and
3) interdisciplinary investigations that may apply to two or three of the BrightFocus disease interests (i.e., Alzheimer's disease, Glaucoma, Macular Degeneration).

Funding Details: Maximum $200,000 for up to 2 years.

Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants Program

The Natural Sciences and Engineering Research Council of Canada (NSERC) is now accepting Notices of Intent to Apply (NOIs) for the 2019 Discovery Grants competition. The Discovery Grants Program supports ongoing programs of research with long-term goals, rather than a single short-term project or collection of projects. These grants recognize the creativity and innovation that are at the heart of all research advances. The objectives of the Discovery Grants Program are to:

- promote and maintain a diversified base of high-quality research capability in the natural sciences and engineering in Canadian universities;
- foster research excellence; and
- provide a stimulating environment for research training.

Funding Details: The final rating assigned, the applicant category, and the outcome of the assessment of the relative costs of research will determine the grant level. Discovery Grants are normally awarded for five years.
Sponsor Deadline: November 1, 2018
*To Apply, Contact Nathan Coschi, Senior Advisor, ROADS at coschimn@mcmaster.ca or extension 21581*

**Weston Brain Institute Rapid Response: Canada 2019 (Parkinson’s & Related Diseases)**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation.

**Funding Details:** A maximum of $200,000 over up to 18 months per project.

**Additional Details**
LOI Deadline: August 1, 2018  
Internal HRS Deadline: October 29, 2018  
Sponsor Deadline: November 12, 2018

**Weston Brain Institute Transformational Research: Canada 2019 (Parkinson’s & Related Diseases)**

NEW for 2018/2019: Accepting applications on diet, physical activity, sleep and nutritional supplements, if these applications meet our other scope criteria. Encouraging applications that bring in expertise, technologies or approaches in the following areas to advance the development of therapeutics and tools for neurodegenerative diseases of aging: artificial intelligence, big data, machine learning, data science, computer science, medicinal chemistry, biostatistics and engineering.

**Funding Details:** A maximum of $1,500,000 over up to 3 years per project.

**Additional Details**
LOI Deadline: August 1, 2018  
Internal HRS Deadline: October 29, 2018  
Sponsor Deadline: November 12, 2018

**Burroughs Wellcome Fund: Investigators in the Pathogenesis of Infectious Disease (PATH) Award**

The Investigators in the Pathogenesis of Infectious Disease program provides opportunities for assistant professors to bring multidisciplinary approaches to the study of human infectious diseases. The goal of the program is to provide opportunities for accomplished investigators still early in their careers to study what happens at the points where the systems of humans and potentially infectious agents connect. The program supports research that sheds light on the fundamentals that affect the outcomes of these encounters: how colonization, infection, commensalism, and other relationships play out at levels ranging from molecular interactions to systemic ones.

**Funding Details:** $500,000 over 5 years

**Additional Details**
LOI Deadline: July 16, 2018  
Internal HRS Deadline: November 1, 2018  
Sponsor Deadline: November 15, 2018

**Canadian Glycomics Network (GlycoNet): GlycoNet Request for Proposals – Cycle II**

A key goal of GlycoNet is to support research projects that are multi-disciplinary, as defined by the NCE program. Accordingly, this Request for Proposals seeks to fund projects that involve two or more research groups in different disciplines. Proposals that involve an investigator who is primarily funded on by one of the tri-council agencies (e.g., CIHR) working with others primarily funded by one or both of the other tri-council agencies (e.g., NSERC and/or SSHRC) will be viewed most favourably.

**Funding Details:** Projects will be funded up to a maximum of $200,000/year and require 1:1 matching. All projects must be completed within 2 years (24 months).
Additional Details
Registration Deadline: July 3, 2018 (registration email to be sent to Karli Buckle – kbuckle@glyconet.ca)
LOI Deadline: August 9, 2018
Internal HRS Deadline: January 18, 2019
Sponsor Deadline: February 1, 2019

Leukemia & Lymphoma Society: Specialized Centre of Research Program
LLS’s Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

Funding Details: The maximal annual total cost is $1,000,000 for each year of the five year grant. The maximum annual direct cost is $833,333.33 while the maximum annual indirect cost is $166,666.66.

Additional Details
LOI Deadline: August 31, 2018
Internal HRS Deadline: February 1, 2019
Sponsor Deadline: February 15, 2019

Lyle Spencer Research Awards
The Lyle Spencer Research Awards Program is intended to support intellectually ambitious research oriented to improving the practice of education, independent of any particular reform agendas or methodological strictures. It supports projects with budgets up to $1 million. In this program, we envision a large-minded conception of educational practice that encompasses formal and informal learning as well as the institutional, policy, and normative frameworks that influence and are influenced by learning and developmental processes. Moreover, we recognize learning occurs across settings—from the classroom to the workplace and even onto the playing field—any of which may, in the right circumstance, provide the basis for rewarding study.

Funding Details: Projects with budgets of up to $1 million are supported.

Additional Details
LOI Deadline: October 2, 2018
Internal HRS Deadline: TBD
Sponsor Deadline: Mid-February 2019

Weston Brain Institute Postdoctoral Scholars at Oxford
The Weston Brain Institute Postdoctoral Scholars at Oxford program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford.

Funding Details: £57,000 per year (£44,000 per year + benefits) for 2 years.

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis, until 2 positions at a time are filled.

Weston Brain Institute International Fellowships: Canada
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Weston Brain Institute is pleased to launch our International Fellowships: Canada program. The program will support top Canadian PhD students to travel to and work in world-renowned international labs for up to 12 months, to further their translational research on neurodegenerative diseases of aging.

Funding Details: $60,000 per year, prorated at $5,000 per month to fit shorter travel and specific project needs
Weston Brain Institute Big Ideas: Canada

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting hypothesis driven, high-risk, high-reward translational research projects of up to $1.5m. Based on success of previous programs, the Institute is expanding our support to new formats while maintaining the same mandate of accelerating the developments of therapeutics for neurodegenerative diseases of aging through translational research. One format they are considering is supporting a large-scale research effort that would provide ~$5-20m over ~5 years in support of a large project(s). With this call, the Institute aims to identify highly impactful ideas for consideration.

Funding Details: From $5,000,000 to $20,000,000

McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities

The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

Funding Details: maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year

MITACS Accelerate Fellowship

The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills. Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

Funding Details:
- Master’s students - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
- PhD students - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

Weston Brain Institute: Early Phase Clinical Trials: Canada

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above, and can be working outside Canada.
An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

**Additional Details**
**Sponsor Deadline:** Ongoing

**OCE Voucher for Innovation and Productivity (VIP I) Program**
The VIP I Program brings industry and academia together to solve industry’s innovation challenges. It helps eligible companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions. The program supports collaborations between industry and post-secondary institutions up to 12 months in duration that lead to knowledge mobilization, commercialization and increased productivity with significant economic impact (i.e. generating new revenues and high-value jobs) for Ontario including the development of new products and/or processes, facilitate productivity improvements. Open to all disciplines, but it has to be a for-profit. Company must have been in operation for a minimum of two years, AND have a minimum of two full-time employees.

**Funding Details:** OCE will support up to 50% of the eligible research costs, to a maximum OCE investment of $20,000.

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

**OCE Voucher for Innovation and Productivity II (VIP II) Program**
The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-secondary institutions’ skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

**Funding Details:** The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000.

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

**MITACS Accelerate Program**
Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

**Funding Details:** Funding starts at $15,000

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

**MITACS Globalink Partnership Award**
The Mitacs Globalink Partnership Award supports research collaborations between graduate students at Canadian universities and international industry partners. The award is open to graduate students in all disciplines at Mitacs, Full, Associate and Honorary Partner universities and for-profit companies in any country (except the United States).
Funding Details: A $15,000 CAD research grant in the Canadian professor’s name to support student travel and accommodation expenses, research-related expenses, and student stipend.

**Additional Details**

**Sponsor Deadline:** Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

### Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) Funding Opportunities for Fiscal Year 2018

The goal of the FY18 TSCR is to fund exploratory, pioneering and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public. Within this context, the FY18 TSCR encourages applications that address the critical needs of the TSC community in one or more of the following FY18 Focus Areas:

- Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
- Improving TSC disease models
- Examining the clinical aspects of TSC, including phenotypic heterogeneity
- Facilitating therapeutics, biomarkers, and clinical trials research

**Funding Details:**

- **Exploration Hypothesis Development Award** - The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $100,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Idea Development Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $450,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- **Clinical Translational Research Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $600,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

**Additional Details**

**LOI Deadline:** July 11, 2018 (A Pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** July 19, 2018

**Sponsor Deadline:** August 2, 2018

### Department of Defense Neurofibromatosis Research Program (NFRP) Funding Opportunities for Fiscal Year 2018

The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY18 Areas of Emphasis. Not all Areas of Emphasis are applicable to each award mechanism offered by the FY18 NFRP. If the proposed research project does not address one of the FY18 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

- Health services research
  - Evidence-based best clinical practices
  - Implementation and access to NF-specific health care
  - Utilization of technology and informatics
- Heterogeneity of neurofibromas and other NF-related tumors
- Nontumor manifestations
  - Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and underreported manifestations
- Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches
  - Transition from benign to malignant
- Nutritional, environmental, and other modifiers of NF
- Post-adolescent manifestations
- Preclinical efficacy studies
• Target identification, drug discovery, targeted and immunotherapies

**Funding Details:**

- **Clinical Trial Award** - The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting a Collaborator). Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

- **Exploration-Hypothesis Development Award** - The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $100,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

- **Investigator-Initiated Research Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $525,000 in direct costs ($575,000 in direct costs if requesting an Optional Qualified Collaborator). Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

- **New Investigator Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $450,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

- **Early Investigator Research Award** - The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $200,000 in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

**Additional Details**

**LOI Deadline:** July 26, 2018 (A Pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 2, 2018

**Sponsor Deadline:** August 9, 2018

**Department of Defense Ovarian Cancer Research Program (OCRP) Funding Opportunities for Fiscal Year 2018**

Ovarian cancer is the leading cause of death among gynecological cancers each year. In 2017, approximately 22,440 women will be diagnosed with ovarian cancer in the United States, and an estimated 14,080 will die from the disease. Ovarian cancer ranks fifth in cancer deaths among women. The Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) was initiated in FY97 to support high-impact, cutting-edge research that fills unmet needs. Appropriations for the OCRP from FY97 through FY16 totaled $276.45 million (M). The FY17 appropriation is $20M.

**Funding Details:**

- **Clinical Development Award** – Maximum Funding of $600,000 for direct and indirect costs for a maximum of 3 years. Funding is increased to $800,000 for direct costs with a qualified nested Early Career Investigator.

- **Omics Consortium Development Award** – Maximum funding of $400,000 for direct and indirect costs for a maximum of 2 years.

- **Ovarian Cancer Academy Award** – Early-Career Investigator – Maximum funding of $725,000 for direct and indirect costs for a maximum of 4 years.

**Additional Details**

**LOI Deadline:** July 25, 2018 (A Pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** August 1, 2018

**Sponsor Deadline:** August 8, 2018

**Department of Defense Medical Simulation and Information Sciences Research Program (JPC-1) Funding Opportunities for Fiscal Year 2018**

The Joint Program Committee-1/Medical Simulation and Information Sciences (JPC-1/MSIS) Research Program plans, coordinates, and oversees a science and technology program focused on improving military medical training and education through medical modeling and simulation systems addressing combat casualty training, medical readiness, health focused initiatives, and developer tools for medical educators as well as improving health information sciences through increased interoperability, strategic planning, process development, and medical applications.
Funding Details:
- FY18 Trauma Resiliency Immersive Adaptive Gaming Environment Award - Anticipated that budgets will not exceed $1.3 million in total costs. Period of performance not to exceed 18 months.

Additional Details
LOI Deadline: June 25, 2018 (A Pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: August 31, 2018
Sponsor Deadline: September 17, 2018

Department of Defense Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for Fiscal Year 2018
The PRMRP is committed to funding research that has the potential to profoundly impact the development and implementation of medical devices, drugs, and clinical guidance that will enhance the precision and efficacy of prevention, diagnosis, and treatment across a wide range of disciplines including cardiovascular health, autoimmune diseases and immunology, infectious diseases, internal medicine, neurological and psychological health, orthopedic and regenerative medicine, and respiratory health and injury. Please see Additional Details link for further information.

Funding Details:
- Clinical Trial Award – No maximum funding limit; requested funding must be appropriate for the scope of work proposed. Maximum period of performance is 4 years.

LOI Deadline: June 25, 2018 (A Pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: September 13, 2018
Sponsor Deadline: September 27, 2018

Department of Defense Kidney Cancer Research Program (KCRP) Funding Opportunities for Fiscal Year 2018
The Department of Defense has released 5 new funding opportunities for their Kidney Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
- Concept Award – Maximum funding of $75,000 for direct costs (plus indirect costs). Maximum period of performance is 1 year. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

LOI Deadline: July 11, 2018 (A Pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: July 25, 2018
Sponsor Deadline: August 8, 2018

Funding Details:
- Idea Development Award – Maximum funding of $400,000 in direct costs (plus indirect costs). Maximum period of performance is 2 years. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- Physician Research Award – Maximum funding of $200,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- Technology Development Award - Maximum funding of $300,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- Translational Research Partnership Award - Maximum funding of $600,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

LOI Deadline: September 5, 2018 (A Pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: September 12, 2018
Sponsor Deadline: September 26, 2018
Department of Defense Lung Cancer Research Program (LCRP) Funding Opportunities for Fiscal Year 2018

The Department of Defense has released 5 new funding opportunities for their Lung Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

**Funding Details:**
- **Concept Award** – Maximum funding of $100,000 in direct costs (plus indirect costs). Period of performance not to exceed 1 year

**LOI Deadline:** July 26, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** August 2, 2018
**Sponsor Deadline:** August 9, 2018

Department of Defense Peer Reviewed Cancer Research Program (P CRP) Funding Opportunities for Fiscal Year 2018

Since Fiscal Year 2009, the Peer Reviewed Cancer Research Program (PRCRP) has been charged by U.S. Congress to fund innovative basic, applied, and translational cancer research to support Service members, their families, and the American public. Members of the military are exposed to hazardous environments due to the nature of their service and deployments and, thus, are at risk for the development of many types of cancers. The mission of the PRCRP is to successfully promote high-impact research for cancer prevention, detection, treatment, and survivorship. Please see Additional Details link for further information.

**Funding Details:**
- **Career Development Award** – Maximum funding for the entire period of performance is $360,000 in direct costs (plus indirect costs). Maximum period of performance is 3 years.

**LOI Deadline:** August 28, 2018 (A Pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** September 12, 2018
**Sponsor Deadline:** September 26, 2018

Department of Defense Tick-Borne Disease Research Program (TBDRP) Funding Opportunities for Fiscal Year 2018

There are currently at least 16 known tick-borne illnesses, with emerging diseases being discovered all the time. In the United States, the yearly cases of Lyme disease and other tick-borne diseases, including spotted fever rickettsiosis, anaplasmosis, and ehrlichiosis,
have been increasing steadily for years, currently totaling tens of thousands of people diagnosed annually, with more likely undiagnosed. Globally, the US Military prioritizes tick-borne Crimean-Congo hemorrhagic fever as an operational threat abroad. The vision of the DoD is to prevent the occurrence, better diagnose and resolve or minimize the impact of Lyme disease and other tick-borne illnesses, with emphasis on burden of disease.

Funding Details:
- **Career Development Award** – Maximum funding of $300K for direct costs (plus indirect costs). Maximum period of performance is 3 years.
- **Idea Award** – Maximum funding of $250K for direct costs (plus indirect costs). Maximum period of performance is 2 years.
- **Investigator-Initiated Research Award** - Maximum funding of $650K for direct costs (plus indirect costs). Maximum period of performance is 3 years.

**Additional Details**
- **LOI Deadline:** June 25, 2018 (A Pre-application is required and must be submitted through eBRAP)
- **Internal HRS Deadline:** September 13, 2018
- **Sponsor Deadline:** September 27, 2018

**Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) Funding Opportunities for Fiscal Year 2018**
The Department of Defense has released 4 new funding opportunities for their Peer Reviewed Alzheimer’s Research Program. Please see Additional Details link for further information.

Funding Details:
- **Convergence Science Research Award (CSRA)** – Maximum funding is $500,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.
- **Quality of Life Research Award (QUAL)** – Funding limit is $500,000 in direct costs. Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.
- **New Investigator Research Award (NIRA)** – Funding limit is $225,000 in direct costs. Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.
- **Research Partnership Award (RPA)** - Funding limit is $1.3 million in total costs. Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.

**Additional Details**
- **LOI Deadline:** September 20, 2018 (A Pre-application is required and must be submitted through eBRAP)
- **Internal HRS Deadline:** September 27, 2018
- **Sponsor Deadline:** October 4, 2018

**Department of Defense Autism Research Program (ARP) Funding Opportunities for Fiscal Year 2018**
The Autism Research Program focuses on improving the lives of those living with ASD by funding innovative, and highly impactful research. Through the program’s areas of interest, the Autism Research Program focuses on ways to improve diagnosis, treatment, and studying psychosocial factors for affecting key life time transitions to independence and a better life for those with autism and their families.

Funding Details:
- **Clinical Trial Award** - The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs).
  - **Early-Career Investigator Partnering PI Option:** The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $1,155,000 for direct costs (plus indirect costs).
- **Idea Development Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs). For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $500,000 in direct costs (plus indirect costs).
- **Clinical Translational Research Award** - The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs).
Department of Defense Epilepsy Research Program (ERP) Funding Opportunities for Fiscal Year 2018

The Department of Defense has released 2 new funding opportunities for their Epilepsy Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
- **Longitudinal Risk Factors Award** - Maximum funding of $2,500,000 for direct costs (plus indirect costs). Maximum period of performance is 4 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.

**LOI Deadline: July 26, 2018** (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline: September 20, 2018**
**Sponsor Deadline: October 4, 2018**

Funding Details:
- **Idea Development Award**
  - **Level I** - Maximum funding of $300,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.
  - **Level II** - Maximum funding of $500,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s rate agreement.

**LOI Deadline: September 20, 2018** (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline: September 27, 2018**
**Sponsor Deadline: October 4, 2018**

Department of Defense Spinal Cord Injury Research Program (SCIRP) Funding Opportunities for Fiscal Year 2018

Spinal cord injuries (SCI) are serious and complex neurotraumatic wounds affecting military service members serving in Iraq and Afghanistan. The SCIRP was established by Congress in FY09 with a $35 million appropriation to support research into regenerating/repairing damaged spinal cords and improving rehabilitation therapies. From FY10-15, Congress appropriated an additional $122.85 million to continue this research. The SCIRP focuses its funding on innovative projects that have the potential to make a significant impact on improving the function, wellness, and overall quality of life for military service members as well as their caregivers, families, and the American public.

Funding Details:
- **Clinical Trial Award** - The maximum allowable funding for the entire period of performance is $3,000,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years.
- **Investigator-Initiated Research Award** - The maximum allowable funding for the entire period of performance is $500,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years.
- **Qualitative Research Award** - The maximum allowable funding for the entire period of performance is $500,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years.
- **Translational Research Award** - The maximum allowable funding for the entire period of performance is $1,250,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years.

Additional Details
Department of Defense Prostate Cancer Research Program (PCRP) Funding Opportunities for Fiscal Year 2018

The Department of Defense has released 6 new funding opportunities for their Prostate Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
- **Physician Research Award** – Maximum funding of $750,000 for direct costs (plus indirect costs). Maximum period of performance is 4 years.
- **Early Investigator Research Award** – Maximum of $200,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years.

LOI Deadline: **August 16, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **August 23, 2018**
Sponsor Deadline: **September 6, 2018**

Funding Details:
- **Idea Development Award** - Maximum funding of $600,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years.

LOI Deadline: **July 6, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **September 13, 2018**
Sponsor Deadline: **September 27, 2018**

Funding Details:
- **Health Disparity Research Award:**
  - **Established Investigators** – Maximum funding of $1,000,000 for direct costs (plus indirect costs).
  - **New Investigators** - Maximum funding of $600,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years.
- **Health Disparity Fellowship Award** - Maximum funding of $200,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years.

LOI Deadline: **September 20, 2018**
Internal HRS Deadline: **September 27, 2018**
Sponsor Deadline: **October 11, 2018**

Funding Details:
- **Impact Award** - Maximum funding of $750,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years.

LOI Deadline: **July 19, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **October 4, 2018**
Sponsor Deadline: **October 18, 2018**

Department of Defense Multiple Sclerosis Research Program (MSRP) Funding Opportunities for Fiscal Year 2018

The etiology and pathogenesis of MS are largely unknown; however, it is thought to be triggered by a combination of one or more environmental factors in a genetically susceptible individual. MS is a heterogeneous disease that can manifest in many ways across the patient population. The progression, severity, and specific symptoms of MS are unpredictable and vary from one person to another. Currently, there is no cure for MS. Since its inception in fiscal year 2009, the Multiple Sclerosis Research Program (MSRP) has supported innovative and impactful research that addresses fundamental issues and gaps in MS. The vision of the MSRP is to prevent, cure, reverse, or slow the progression and lessen the personal and societal impact of MS.
Funding Details:
- **Investigator Initiated Research Award** – Anticipated that budgets will not exceed $600,000 in direct costs (plus indirect costs). Period of performance not to exceed 3 years.
- **Exploration – Hypothesis Development Award** - Anticipated that budgets will not exceed $150,000 in direct costs (plus indirect costs). Period of performance not to exceed 2 years.

**Additional Details**
LOI Deadline: June 26, 2018 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: October 4, 2018
Sponsor Deadline: October 18, 2018

**Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) Funding Opportunities for Fiscal Year 2018**
A large majority of the injuries sustained by military personnel in U.S. war efforts involve soft tissue wounds and skeletal fractures, pointing to an urgent need for orthopaedic research that will provide superior medical care and treatment options for injured service members. Orthopaedic injuries sustained during combat-related activities tend to be very heterogeneous and complex in nature, typically involving multiple tissues, such as skin, bone, muscle, cartilage, and nerves.

Funding Details:
- **Applied Research Award** – Maximum funding of $750,000 for total costs (includes direct and indirect costs). Maximum period of performance is 3 years.
- **Clinical Trial Award** – Maximum funding of $3 million (M) for total costs (includes direct and indirect costs). Maximum period of performance is 4 years.
- **Clinical Translational Research Award** - Maximum funding of $2M for direct costs (plus indirect costs). Maximum period of performance is 4 years.

**Additional Details**
LOI Deadline: July 30, 2018 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: October 10, 2018
Sponsor Deadline: October 24, 2018

**Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) Funding Opportunities for Fiscal Year 2018**
The Orthotics and Prosthetics Outcomes Research Program, OPORP, was established by congress in fiscal year 2014 to support military relevant personal assistive technology outcomes research. The goal of the OPORP is to improve our understanding and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers.

Funding Details:
- **Clinical Research Award (CRA):**
  - **Funding Level 1** - Maximum funding of $350,000 for total costs (direct costs plus indirect costs). Maximum period of performance is 2 years.
  - **Funding Level 2** - Maximum funding of $1,500,000 for total costs (direct costs plus indirect costs). Maximum period of performance is 4 years.
- **Clinical Trial Award (CTA):**
  - **Funding Level 1** – Maximum funding of $350,000 for total costs (direct costs plus indirect costs). Maximum period of performance is 2 years.
  - **Funding Level 2** - Maximum funding of $2,500,000 for total costs (direct costs plus indirect costs). Maximum period of performance is 4 years.

**Additional Details**
LOI Deadline: August 6, 2018 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: October 11, 2018
Sponsor Deadline: October 25, 2018
Department of Defense Bone Marrow Failure Research Program (BMFRP) Funding Opportunities for Fiscal Year 2018

The objective of the FY18 BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator-initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF diseases and their progressions to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies and translational projects including bone marrow transplantation studies should be clearly related to BMF diseases.

Funding Details: Maximum funding of $325,000 for direct and indirect costs for a maximum of 2 years.

Additional Details
LOI Deadline: July 16, 2018 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: October 18, 2018
Sponsor Deadline: November 1, 2018

Department of Defense Lupus Research Program (LRP) Funding Opportunities for Fiscal Year 2018

The Lupus Research Program (LRP) was first funded in FY17 to support innovative and impactful research that addresses significant issues and gaps in lupus. Lupus is a heterogeneous autoimmune disease that is difficult to diagnose and treat. There is currently no test available to diagnose lupus and it may take months or years for a person to be correctly diagnosed. Because lupus attacks healthy cells and tissues in many parts of the body, patients can experience a wide range of symptoms such as fatigue, joint pain, skin lesions, and headaches. Lupus can also cause inflammation in the kidneys, brain, blood vessels, lungs, and heart which can result in serious complications including organ damage. Lupus patients require a diverse team of healthcare specialists depending on their symptoms.

Funding Details:
- **Concept Award** – The maximum period of performance is 1 year. The maximum allowable funding for the entire period of performance is $150,000 in total costs.
- **Impact Award** – The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $525,000 in total costs.

Additional Details
LOI Deadline: October 10, 2018 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: October 24, 2018
Sponsor Deadline: November 7, 2018

Department of Defense Gulf War Illness Research Program (GWIRP) Funding Opportunities for Fiscal Year 2018

The GWIRP focuses on funding innovative, competitively peer-reviewed research to (1) provide a better understanding of the pathobiology underlying GWI, (2) identify objective markers (biomarkers) for improved diagnosis, and (3) to develop treatments for the complex of GWI symptoms and their underlying causes. Our Vision is to make a significant impact on GWI and improve the health and lives of affected Veterans and their families.

Funding Details:
- **Clinical Trial Award** - Maximum funding of $1,000,000 for direct costs (plus indirect costs). Maximum funding of $1,016,000 for direct costs with the Biorepository Contribution Option (plus indirect costs). Maximum period of performance is 4 years.
- **Investigator-Initiated Focused Research Award** - Maximum direct costs and period of performance vary based on Tier
  - Discovery Tier: Maximum funding of $230,000 or 246,000 with the Biorepository Contribution Option for direct costs (plus indirect costs) for a maximum of 2 years.
  - Applied Research Tier: Maximum funding of $700,000 or $716,000 with the Biorepository Contribution Option for direct costs (plus indirect costs) for a maximum of 3 years.
- **Qualitative Research Award** - Maximum funding of $400,000 for direct costs (plus indirect costs). The maximum period of performance is 3 years.

Additional Details
Department of Defense Hearing Restoration Research Program (HRRP) Funding Opportunities for Fiscal Year 2018

The HRRP was initiated in 2017 to pursue promising, necessary research for treatment of burdensome and very prevalent auditory system injury. It is estimated that more than 30 million Americans over the age of 12 years have hearing loss in both ears and an estimated 48 million have hearing loss in at least one ear. In the military the two most prevalent service-connected disabilities are related to hearing disorders. The most recent data from the Veterans Benefits Administration, Department of Veterans Affairs indicates that there are 1.1 million Veterans with service-connected disability due to hearing loss. The HRRP will fund innovative research that has the potential to maximize operational effectiveness, medical readiness and quality of life for Service members, Veterans and others living with significant auditory system injuries.

Funding Details:

- **Translational Research Award (TRA)** – Maximum funding of $1,000,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs budgeted must be in accordance with the institution’s rate agreement.
- **Focused Applied Research Award (FARA)** - Maximum funding of $1,000,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs budgeted must be in accordance with the institution’s rate agreement.

Additional Details

LOI Deadline: **July 17, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **October 25, 2018**
Sponsor Deadline: **November 8, 2018**

Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) Funding Opportunities for Fiscal Year 2018

Duchenne muscular dystrophy (DMD) affects approximately 1 out of every 3,500 male infants (about 20,000 new cases a year). This form of muscular dystrophy results from mutations in the dystrophin gene that lead to an absence of dystrophin in muscle cells, allowing these cells to be easily damaged. Boys living with DMD experience devastating muscle weakness that affects the skeletal muscles, heart, and respiratory muscles. Symptoms of DMD typically develop prior to age 5, and by age 12 most patients are confined to a wheelchair.

Funding Details:

- **Investigator-Initiated Research Award** - Maximum funding of $600,000 in direct costs (plus indirect costs) Period of performance not to exceed 3 years. Optional Interdisciplinary Collaborator: Additional maximum of $150,000 in direct costs over the 3-year period of performance. Optional Nested Traineeship: Additional maximum of $50,000 for residents or $30,000 for medical students in direct costs (plus indirect costs) over a 1-year period of performance.
- **Career Development Award** - Maximum funding of $275,000 in direct costs (plus indirect costs) Period of performance not to exceed 2 years.

Additional Details

LOI Deadline: **August 29, 2018** (Investigator-Initiated Research Award)
   **November 14, 2018** (Career Development Award)
(A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **November 21, 2018**
Sponsor Deadline: **December 5, 2018**